LGVN
LGVN
NASDAQ · Biotechnology

Longeveron Inc-A

$2.63
-0.18 (-6.41%)
As of Sep 28, 10:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
2.21M
Net Income
-41,777,288
Gross Margin
67.0%
Profit Margin
-1,893.6%
Rev Growth
-0.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.0% 67.0% 43.6% 43.6%
Operating Margin -1,942.2% -1,748.0% -2.2% -2.6%
Profit Margin -1,893.6% -1,798.9% -2.4% -2.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.21M 2.22M 3.54M 3.93M
Gross Profit 1.48M 1.49M 1.54M 1.71M
Operating Income -42,852,623 -38,811,875 -77,362 -100,425
Net Income -41,777,288 -37,837,938 -86,327 -108,943
Gross Margin 67.0% 67.0% 43.6% 43.6%
Operating Margin -1,942.2% -1,748.0% -2.2% -2.6%
Profit Margin -1,893.6% -1,798.9% -2.4% -2.8%
Rev Growth -0.6% -0.6% +8.8% +5.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 4.00M 4.40M
Total Equity — — 6.27M 5.45M
D/E Ratio — — 0.64 0.81
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -40,592,264 -38,807,135 -134,724 -147,370
Free Cash Flow — — -61,141 -91,187